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IMPORTANCE Various factors have been proposed as possible candidates associated with the
prognosis of amyotrophic lateral sclerosis (ALS); however, there is still no consensus on which
biomarkers are reliable prognostic factors. C-reactive protein (CRP) is a biomarker of the
inflammatory response that shows significant prognostic value for several diseases.
OBJECTIVE To examine the prognostic significance of CRP in ALS.
DESIGN, SETTING, AND PARTICIPANTS Patients’ serum CRP levels were evaluated from January
1, 2009, to June 30, 2015, in a large cohort of patients with ALS observed by an Italian tertiary
multidisciplinary center. Results were replicated in an independent cohort obtained from a
population-based registry of patients with ALS. A post hoc analysis was performed of the
phase 2 trial of NP001 to determine whether stratification by levels of CRP improves
differentiation of responders and nonresponders to the drug.
MAIN OUTCOMES ANDMEASURES Serum CRP levels from the first examinationwere recorded
to assess their effect on disease progression and survival.
RESULTS A total of 394 patients with ALS (168 women and 226men; mean [SD] age at
diagnosis, 60.18 [13.60] years) were observed in a tertiary multidisciplinary center, and the
analysis was replicated in an independent cohort of 116 patients with ALS (50women and
66men; mean [SD] age at diagnosis, 67.00 [10.74] years) identified through a regional
population-based registry. Serum CRP levels in the 394 patients with ALS correlated with
severity of functional impairment, as measured by total score on the ALS Functional Rating
Scale–Revised, at first evaluation (r = –0.14818; P = .004), and with patient survival (hazard
ratio, 1.129; 95% CI, 1.033-1.234; P = .007). Similar results were found in the independent
cohort (hazard ratio, 1.044; 95% CI, 1.016-1.056; P  .001). Moreover, a post hoc analysis of
the phase 2 trial of NP001 using the same CRP threshold showed that patients with elevated
baseline CRP levels receiving the higher dose of NP001 had significantly less functional
impairment after the treatment period compared with patients with normal baseline CRP,
regardless of whether patients with normal CRP levels received NP001 or placebo (3.00
[3.62] vs –7.31 [6.23]; P = .04).
CONCLUSIONS AND RELEVANCE These findings suggest that patients with ALS and elevated
serum CRP levels progress more rapidly than do those with lower CRP levels and that this
elevationmay reflect a neuroinflammatory state potentially responsive to the immune
regulators such as NP001.
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Amyotrophic lateral sclerosis (ALS) is a severe neurode-generative disorder with a fatal outcome and a meansurvival time ranging from 2 to 5 years.1 No treatment
is currently available to modify the disease process of ALS.
Age,2,3 site of onset,2 functional and respiratory status,4-6 cog-
nitive dysfunction,7 clinical phenotypes,8,9 serum triglycer-
ide and cholesterol levels,10-12 creatinine level,3,13 albumin
level,13 and C9orf72 expansion14 have been proposed as pos-
sible candidates associated with the prognosis of ALS. How-
ever, there is still no consensus onwhich biomarkers are reli-
able prognostic factors in ALS.15
C-reactive protein (CRP) is an acute-phase protein regu-
lated by proinflammatory cytokines and secreted by hepato-
cytes during the inflammatory response.16 C-reactive protein
is referred to as a pentraxin because of its capacity to aggre-
gate, in a noncovalent fashion, into flat pentameric discs. The
pentraxins are presumed to have great survival value and to
be intimately associated with innate immune defense.17,18
C-reactive protein is a biomarker of the inflammatory re-
sponsewith a significant prognostic value for several types of
tumors,19,20 cardiovascular diseases,21 and rheumatic
diseases.22Recently,Milleretal23presented the resultsofa ran-
domized phase 2 clinical trial of a novel immune regulator,
NP001, inALS (NCT01281631). Although the results of the trial
were negative, they showed that patients treatedwithNP001
whosebaselineCRP levelswereabove themedian for theentire
randomized population had a slower progression of ALS than
did patients with the same elevated baseline CRP levels who
received placebo.
Previously, Keizman et al24 found in a small group of pa-
tients with ALS a significant correlation between the clinical
disability and some sensitive biomarkers of inflammation, in-
cluding CRP. To fully examine the prognostic significance of
CRP in ALS, we evaluated its serum levels at first evaluation
ina large cohort ofpatientswithALSobserved inan Italian ter-
tiarymultidisciplinary center. We replicated the results in an
independent cohort from a population-based registry of pa-
tients with ALS. Finally, we performed a post hoc analysis of
the phase 2 trial of NP001 to evaluate if CRP may contribute
to the identification of responders to the drug.
Methods
Analysis of Prognostic Value of CRP
We retrospectively collected data from 394 patients who re-
ceived a diagnosis of ALS based on a detailed history, physi-
cal examination, andelectrophysiologic evaluation25 andwho
were living in the Lombardy region and in other adjacent Ital-
ian regions at the time of their initial visit to the NeuroMus-
cular Omnicentre (NEMO), a tertiarymultidisciplinary center
inMilan, between January 1, 2009, andDecember 31, 2014.All
patientsmet the revisedElEscorial diagnostic criteria for defi-
nite, probable, andprobable laboratory-supportedALS.26 The
ALSFunctional Rating Scale–Revised (ALSFRS-R)wasused to
assess disease severity.27 Assessments were repeated every 3
months until June 30, 2015. Patients with any clinical evi-
dence of acute infection or chronic active inflammatory dis-
ease, such as rheumatoid arthritis, were excluded. The study
design was approved by the institutional ethical committees
of Niguarda Ca’ Granda Hospital. Patients provided written
informed consent.
To validate the results obtained in the NEMO cohort, we
replicated the analysis in a cohort consisting of 122 patients
with ALS at different stages of the disease who were identi-
fied through the Piemonte and Valle d’Aosta Register for ALS
(PARALS)28 and evaluated at the ALS Center of the “Rita Levi
Montalcini”DepartmentofNeuroscience andAziendaOsped-
ale Università, Città della Salute e della Scienza, Turin, Italy,
between January 1, 2009, and December 31, 2009.
To determine the prognostic value of CRP, serum levels
were evaluated at enrollment and correlatedwith the clinical
demographics of patients with ALS, such as age at diagnosis,
sex, duration of disease at time of evaluation, site of onset,
ALSFRS-R total score, body mass index, smoking status, and
survival. To standardize the threshold that defineshigher and
lower CRP levelswithin the 3 centers,we arbitrarily chose the
median value (0.20mg/dL [to convert to nanomoles per liter,
multiply by 9.524]) obtained in the NEMO cohort to subdi-
vide patients into the normal CRP group (CRP, ≤0.20 mg/dL)
and the elevated CRP group (CRP, >0.20mg/dL). This thresh-
old was used for all subsequent evaluations.
Post Hoc Analysis of the Phase 2 Trial of NP001
The phase 2 trial of NP001 was a randomized, double-blind,
placebo-controlled clinical trial of patients with probable or
definiteALSaccording toElEscorial criteria conductedbyNeu-
raltus Pharmaceuticals from January 2011 through Novem-
ber2012 in theUnitedStates.23Patientswereallocated ina 1:1:1
manner to receive 1 mg/kg of NP001, 2 mg/kg of NP001, and
placebo. Patients received a total of 20 infusions for 6 cycles
duringa25-weekdouble-blind treatmentperiod.Forourstudy,
NeuraltusPharmaceuticalsprovidedclinicaldata fromthetrial,
including the ALSFRS-R scoresmeasured every 4 weeks dur-
ing the trial and for a further 3 months after the end of treat-
ment. To determine the value of CRP in detecting responders
to the treatment, we evaluated serum CRP levels at enroll-
ment and then subdivided patients into a normal CRP group
and elevated CRP group.
Key Points
Question Is serum C-reactive protein a prognostic biomarker in
amyotrophic lateral sclerosis (ALS)?
Findings In this cohort study of 394 patients with ALS, serum
C-reactive protein levels at the first examination correlated with
the degree of disability and with survival in patients with ALS.
Moreover, a post hoc analysis of a phase 2 trial of NP001 showed
that patients with elevated baseline serum C-reactive protein
levels who received the higher dose of NP001 had significantly
less functional impairment compared with other patients.
Meaning Patients with ALS and elevated serum C-reactive protein
levels progress more rapidly than do those with lower levels; this
elevationmay reflect a neuroinflammatory state potentially
responsive to immune regulators such as NP001.
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Statistical Analysis
Statistical analyseswere performedwith SASversion9.3 (SAS
Institute Inc). Data are reported as mean (SD) values for con-
tinuous variables and numbers for noncontinuous variables.
For each variable, we used the Shapiro-Wilk test to evaluate
thenormality of thedistribution and theLevene test to evalu-
ate the homogeneity of variance.We used 2-tailed t tests and
nonparametricWilcoxonrank-sumtests asappropriate.Fordi-
chotomous variables, we used the χ2 test. P < .05was consid-
ered statistically significantwithBonferroni adjustment for all
tests. Correlation analysis was performed using the Pearson
correlation coefficient for variableswith normal distribution,
the nonparametric Spearman rank correlation coefficient for
the others, and the multivariable regression model adjusted
for age, sex,bodymass index, andsmokingstatus (withα < .05
considered significant).
To determinewhether the serumCRP level was indepen-
dently associated with survival, we used a multivariable Cox
proportional hazards regression model and Kaplan-Meier
analysis. To validate the prognostic value of the serum CRP
level, we applied the same analyses to the validation cohort.
For theposthocNP001analysis, theprimaryendpointwas
the change in ALSFRS-R score from baseline through the end
of the treatment period and follow-up. To analyze the effect
ofNP001 (both the 1- and2-mg/kgdose)orplacebo, eachgroup
wasdivided intonormalCRPandelevatedCRPsubgroups, and
the nonparametric Wilcoxon rank-sum test was used.
Results
Analysis of CRP Prognostic Value
Baseline characteristics of the NEMO cohort and the PARALS
cohort are summarized in theTable. Patients in theNEMOco-
hort were younger (mean [SD] age at diagnosis, 60.18 [13.60]
years vs 67.00 [10.74] years;P < .001),with a lowermean (SD)
ALSFRS-R score at baseline (31.26 [10.08] vs 38.84 [8.21]) and
ashortermean (SD) survival time (21.66 [17.26]monthsvs31.72
[21.93] months) compared with those in the PARALS cohort.
In theNEMOcohort, CRPwasnot correlatedwithageatdi-
agnosis (r = 0.06812; P = .19), sex (r = 0.00794; P = .65), dis-
easedurationat timeofevaluation (r = 0.01154;P = .97),or site
ofonset (r = 0.04776;P = .19).TheCRP levelwas inversely cor-
relatedwith the ALSFRS-R total score (r = –0.14818; P = .004),
and this correlation remained significant even when adjusted
for age, sex, body mass index, and smoking status (standard-
izedβ,–0.13499;P = .04) (Figure1). InthemultivariableCoxpro-
portional hazards regression model and Kaplan-Meier analy-
sis, the elevatedCRPgrouphad a significantly shorter survival
comparedwith thenormalCRPgroup (hazard ratio, 1.129; 95%
CI, 1.033-1.234;P = .007; 22.94 [16.97] vs 19.79 [17.57]months;
P = .02) (eTable 1 in theSupplement;Figure2). ThePARALSco-
hort confirmed that patientswithALS and elevatedCRP levels
had shorter survival comparedwith other patients (hazard ra-
tio, 1.044; 95%CI, 1.016-1.056;P ≤ .001; 37.03 [22.89] vs 29.52
[21.27]months;P = .04) (eTable 1 in theSupplement;Figure2).
To evaluate whether the changes in CRP level over time
were correlated with the changes in the ALSFRS-R score, we
reviewed the available records of a group of 50patients in the
NEMOcohortwhowere evaluated in 3 consecutive follow-up
visits during 1 year of observation.We correlated the slope of
the ALSFRS-R score with the slope of serum CRP levels and
found that this correlation was significant (r = –0.37811;
P < .001) even when adjusted for age, sex, body mass index,
and smoking status (eFigure in the Supplement).
Figure 1. Serum C-Reactive Protein (CRP) Levels and Disease Progression
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Scale–Revised (ALSFRS-R) score and serum CRP levels (r = 0.14818; P = .04) (to
convert to nanomoles per liter, multiply by 9.524).
Table. Demographics and Clinical Characteristics of PatientsWith ALS in Both Cohorts at Inclusion
Characteristic
NEMO Cohort
(n = 394)
Validation Cohort
(n = 116) P Value
Age at diagnosis, mean (SD), y 60.18 (13.60) 67.00 (10.74) <.001
Sex, No. (%) .93
Male 226 (57.4) 66 (56.9)
Female 168 (42.6) 50 (43.1)
Site of onset, No. (%) .74
Bulbar 115 (29.2) 35 (30.2)
Limb 279 (70.8) 81 (69.8)
ALSFRS-R total score, mean (SD) 31.26 (10.08) 38.84 (8.21) <.001
Disease duration, mean (SD), moa 11.23 (9.32) 12.00 (11.28) .46
Survival, mean (SD), mob 21.66 (17.26) 31.72 (21.93) <.001
Abbreviations: ALS, amyotrophic
lateral sclerosis; ALSFRS-R,
Amyotrophic Lateral Sclerosis
Functional Rating Scale–Revised;
NEMO, NeuroMuscular Omnicentre;
PARALS, Piemonte and Valle d’Aosta
Register for ALS.
a Interval between the onset and
diagnosis.
b Interval between first evaluation of
disease and death, tracheostomy, or
censoring date.
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Post Hoc Analysis of the Phase 2 Trial of NP001
Thepost hoc analysis includeddata from113patients, exclud-
ing 23 patients with missing information about disease pro-
gression after the end of the treatment period. eTable 2 in the
Supplement summarizes the demographic and clinical char-
acteristics at baseline of patients in each treatment group
(1 mg/kg of NP001, 2mg/kg of NP001, and placebo). Baseline
medianCRP levelswere similar betweengroups (1.41mg/L for
thepatientswho received 1mg/kgofNP001,0.96mg/L for the
patients who received 2 mg/kg of NP001, and 1.03 mg/dL for
the patients who received placebo). There were no signifi-
cant clinicaldifferencesatbaselinebetweengroups, except for
mean (SD)diseaseduration,whichwashigher in the group re-
ceiving 1 mg/kg of NP001 than in the other 2 groups (22.52
[9.40]months for thepatientswho received 1mg/kgofNP001,
17.23 [8.36] months for the patients who received 2 mg/kg of
NP001, and 16.85 [8.26] months for the patients who re-
ceivedplacebo;P = .007). In linewithpreviousanalyses,NP001
in both dose groups did not have a statistically significant ef-
fectonreducingALSprogressioncomparedwithplacebo.How-
ever, whenwe subdivided each treatment group according to
CRP level at enrollment (normal CRP group and elevated CRP
group),we found that forpatients treatedwith thehigherdose
ofNP001 (2mg/kg), thedecrease in themeanALSFRS-R score
in the elevated CRP group was less than half the decrease in
thenormalCRPgroup for all periods following theendof treat-
ment (weeks 25, 29, 33, and 37) (eTable 3 in the Supplement;
Figure 3). One evaluation point, week 33, showed a statisti-
cally significant difference in the decrease in mean ALS-
FRS-Rscoreamong thegroupreceiving2mg/kgofNP001 (nor-
mal CRP level, –7.31 mg/L; elevated CRP level, –3.00 mg/L;
P = .045).Moreover, using the samesubgroups to compare the
NP001 arms with placebo, we found that patients in the el-
evatedCRPgroup receiving thehigher dose ofNP001had sig-
nificantly less functional impairment (eTable 4 in the Supple-
ment;Figure4).Again,after theendof treatment,patientswith
elevated serum CRP levels who were receiving 2 mg/kg of
NP001hadstatistically significantdecreases inALSFRS-Rscore
of less than half the decrease of patients receiving placebo at
weeks 29 (–2.1 vs –6.7; P = .01), 33 (–3.0 vs –8.0; P = .03), and
37 (–3.7 vs –9.0; P = .03). More important, there appeared to
be a dose-response association in patients with elevated se-
rum CRP levels and no discernible difference between the
NP001 and placebo arms in patients with normal baseline
serum CRP levels (Figure 4).
Discussion
We have analyzed the prognostic significance of CRP in ALS,
evaluating its serum levels at first evaluation in a large cohort
of patients with ALS in an early phase of the disease (as ex-
pressed by a disease duration <20months from first onset of
symptoms) without an active inflammatory process and ob-
served in an Italian tertiary multidisciplinary center. In our
analysis, CRP level was not correlated with age at diagnosis,
sex, disease duration, or site of onset of ALS. Serum CRP lev-
els were correlated with the severity of functional impair-
ment, as measured by ALSFRS-R total score; this correlation
was independent frompatients’ age, sex,bodymass index,and
smoking status. Moreover, evaluating a group of 50 patients
with ALS in a year of follow-up visits, we found a significant
negative correlationbetween the slopeof theALSFRS-R score
and the slope of serum CRP levels, emphasizing the signifi-
cance of the serumCRP level as a useful, feasible, and poten-
tially prognostic factor in patients with ALS.
Moreover, the serum CRP level was significantly corre-
latedwithpatient survival, showing thatpatientswithALSand
elevated serum CRP levels at first evaluation had a signifi-
cantly shorter survival compared with those with normal se-
rumCRP levels. Similar resultswere found in an independent
cohort obtained from a population-based registry of patients
with ALS. In particular, according to the hazard ratio evalu-
ated in discovery and validation cohorts, for every 1-point in-
Figure 2. Serum C-Reactive Protein (CRP) Levels and Survival
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crease in the serum CRP level, we detected an effect of 13%
(hazard ratio, 1.129; 95% CI, 1.033-1.234) and 4% (hazard ra-
tio, 1.044; 95%CI, 1.016-1.056), respectively, on survival time
in thepatientswithALSevaluated inour study (eTable 1 in the
Supplement). These data suggest that serum CRP levels may
be useful as a prognostic biomarker in patients with ALS.
Both acute and chronic inflammation stimulates the re-
lease of proinflammatory cytokines, mainly IL-6, into the
bloodstream. The liver responds to this release by producing
acute-phase reactants such as CRP, which is the most com-
monly used marker of an acute-phase reaction and was first
discovered in the serum of patients with pneumococcal
pneumonia.29 Thus, our study supports the importance of in-
flammation in ALS and that CRP may represent a simple bio-
marker obtainable from blood samples from each patient in-
dependent of his or her clinical condition. Some studies also
showed an increment of CRP in the cerebrospinal fluid of pa-
tientswithALS, emphasizing the significanceofneuroinflam-
mation in the disease.30-32
C-reactiveprotein is an invivo activator of complement.33
The complement pathway has been postulated to contribute
tomotor neuron disease, and levels of complement proteins,
includingC3, havebeen shown tobe increased in the cerebro-
spinal fluid and spinal cord tissue of patients with ALS.34-36
Therefore,CRPmaycontribute to theactivationof thecomple-
ment pathway inmotor neuron disease. Activation of inflam-
matory and complement pathways is not specific to ALS or
other neurodegenerative diseases. However, in cerebrospi-
nal fluid, thephosphorylatedneurofilamentheavychaintoCRP
ratioshowedsignificantdifferences inALScomparedwithboth
disease controls and healthy control groups, suggesting that
inclusionofgeneral inflammatoryresponsesallowsmorespeci-
ficity in identifying ALS.37 High CRP levels increase perme-
ability of the blood-brain barrier38 and elicit microglial acti-
vation in the brain.39 Results of animal studies showed that
systemic inflammation contributes to the neurodegenerative
process throughmicroglial activation.32,40,41
It hadbeengenerallybelieved formanyyears thatCRPwas
producedonly in the liverandcarried in thecirculation toother
organs.Molecular genetic techniques have demonstrated that
CRP can be produced locally in the brain and that its produc-
tion of CRP is sharply upregulated in areas damaged by neuro-
degenerativeprocesses, as inAlzheimerdisease.42Neuronsare
the most prominent generators of CRP in the central nervous
system.42,43 InAlzheimerdisease,CRP is associatedwithdam-
aged fibers within senile plaques.44 In our study, the signifi-
cant correlationof serumCRP levelwithneurologic functional
impairmentandsurvival inpatientswithALS in theearlyphase
of thediseaseandwithoutanactive inflammatoryprocess sup-
ports the hypothesis that the increment of CRP in the periph-
eral bloodmaybe themirrorof theupregulationof theproduc-
tion of CRP in the central nervous system. Recently, Lu et al45
showedthat thecytokine IL-6wasstronglyassociatedwithCRP
levels andwas the onlymarker showing increasing expression
toward end-stage disease in the longitudinal analysis. In a ret-
rospective analysis, patients with Parkinson disease and el-
evatedCRP levels atbaselinehada significantly shortenedsur-
vival comparedwith thosewithnormalCRP levels.46Moreover,
CRP has been associated with severity of functional impair-
ment in other neuromuscular disorders. In particular, in pa-
tients with Duchenne muscular dystrophy, high levels of CRP
(mean, 3.94 md/dL) were associated with poor functional im-
pairment and obesity.47 In another study, CRP was signifi-
cantly higher (mean, 0.99 mg/dL) in patients with type 2 dia-
betesandperipheralneuropathycomparedwiththosewithtype
2diabeteswithoutperipheralneuropathy(mean,0.25mg/dL).48
In our study, we also used the serum CRP level as a bio-
marker tobetter stratify respondersornonresponders to treat-
Figure 3. Role of Serum C-Reactive Protein (CRP) Levels as Therapeutic Biomarker
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A, Mean change from baseline in Amyotrophic Lateral Sclerosis Functional
Rating Scale–Revised (ALSFRS-R) score in patients receiving NP001, 1-mg/kg
dose, in the normal CRP group (CRP,0.20mg/dL [to convert to nanomoles
per liter, multiply by 9.524]) and elevated CRP group (CRP, >0.20mg/dL) at first
evaluation (P = .19). B, Mean change from baseline in ALSFRS-R score in
patients receiving NP001, 2-mg/kg dose, in the normal CRP group and elevated
CRP group at first evaluation (P = .045). C, Mean change from baseline in
ALSFRS-R score in patients receiving placebo in the normal CRP group and
elevated CRP group at first evaluation (P = .70). The vertical line indicates the
end of the treatment period.
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ment with NP001, a pH-adjusted intravenous formulation of
purified sodium chlorite that regulates inflammation in vitro
and invivo.49NP001 is anovel regulatorof inflammatorymac-
rophagesandmonocytes thatdownregulatesnuclear factorkB
expression and inhibits production of the proinflammatory
cytokine IL-1b.24,50-53 These mechanisms of downregulation
transformmonocytes andmacrophages fromaproinflamma-
tory state to a basal phagocytic state. The randomized phase
2 clinical trial showed that NP001 did not significantly slow
disease progression in patients with ALS. However, the re-
sults of the study suggested a slowing of progression in the
high-dose group among patients with elevated levels of in-
flammation. In our study, we performed a post hoc analysis
of the phase 2 trial ofNP001,which showed that, in the group
of patients treated with the higher dose of NP001, the wors-
ening of functional impairment after the end of the treat-
mentwas significantly less in patientswith elevated CRP lev-
els compared with those with normal CRP levels. When
comparedwith thepatients in theplacebogroup,patientswith
elevated CRP levels at baseline showed a significant NP001
dose-dependent slowing in loss of function as measured by
change from baseline ALSFRS-R scores.
Moreover, our studyemphasizes the importanceof devel-
oping treatments tocontroldiseaseprocesses that increase lev-
els of CRP or pentraxin activity. Because pentraxin activity is
associated with activation of the complement cascade, im-
munomodulatory agents such as NP001mightmitigate com-
plications of an autotoxic attack thought tobe associatedwith
neurodegenerative diseases.42
Limitations
Although our results are encouraging, there are some limita-
tions to the study. First, the number of patients includedwas
limited, in particular, in the group of patients with consecu-
tive follow-up visits. Second, we did not correlate the serum
CRP levelwith other peripheral neuroinflammatory biomark-
ers or with the cerebrospinal fluid CRP levels.
Conclusions
Our findings confirm that CRPmaybeusedboth as aprognos-
tic factorandabiomarker tostratifypatientswithALSwhohave
a more prominent neuroinflammatory process that may re-
Figure 4. Role of Serum C-Reactive Protein (CRP) Levels to Detect ALS Patients Possibly Responsive
to Treatment
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A, Mean change from baseline in
Amyotrophic Lateral Sclerosis
Functional Rating Scale–Revised
(ALSFRS-R) score in patients in the
normal CRP group (CRP,0.20
mg/dL [to convert to nanomoles per
liter, multiply by 9.524]) receiving
NP001, 1-mg/kg dose, vs placebo.
B, Mean change from baseline in
ALSFRS-R score in patients in the
normal CRP group receiving NP001,
2-mg/kg dose, vs placebo. C, Mean
change from baseline in ALSFRS-R
score in patients in the elevated CRP
group (CRP, >0.20mg/dL) receiving
NP001, 1-mg/kg dose, vs placebo.
D, Mean change from baseline in
ALSFRS-R score in patients in the
elevated CRP group receiving NP001,
2 mg/kg/dose, vs placebo. Patients
in the elevated CRP group receiving
the higher dose of NP001 had
significantly less functional
impairment at weeks 29 (P = .01),
33 (P = .03), and 37 (P = .03).
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spond to targeted treatments. However, further analyses in
larger cohortsofpatientswithALS, aswell as studiesusing lon-
gitudinal samples to detect how CRP levels really reflect the
rate of progression anddisease states, are needed to justify its
use as aprognostic peripheral biomarker for patientswithALS
with a significant central nervous system inflammatory pro-
cess. In this context, these studiesmaybeuseful todetecthow
theCRP levels changeover time inpatientswithALSwhohave
higher initial CRP levels andmore rapid progression, or in pa-
tients with lower initial CRP levels.
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